Cathepsin B is a cysteine protease found mainly in the lysosomes of normal cells but is secreted or associated with the plasma membrane of many transformed cells. It is found in all animals and other organisms and plays a key role in cellular protein metabolism. The cathepsin family includes serine proteases, aspartic proteases, and cysteine proteases. The aspartyl protease class consists of cathepsins D and E. The cysteine protease class consists of cathepsins B, L, H, K, S, and O. Currently, there are no approved cathepsin inhibitors on the market, but research is ongoing to develop new cathepsin inhibitors for the treatment of various diseases such as cancer, traumatic brain injury, Ebola infection, and others. Anti-Cathespin B antibodies are majorly used for the treatment of disease conditions such as cancer, traumatic brain injury, Ebola infection, and fertility problems, and are currently under research for the treatment of SARS-CoV-2. Cathepsin B is a protease that contributes to the remodeling of the extracellular matrix and thereby promotes keratinocyte migration during wound healing.

Market Dynamics

Increasing practices of treatments, mergers, and acquisitions by key market players are expected to drive the global anti-cathepsin B market growth. For instance, on March 31, 2020, National Center for Biotechnology Information published an article explaining Cathepsin B (CTSB) is an abundant cysteine protease that functions in both endolysosomal compartments and extracellular regions. Many preclinical and clinical studies indicate that CTSB is involved in many human diseases. CTSB expression levels and activity are significantly correlated with disease progression and severity. Current CTSB inhibitors lack sufficient specificity and pharmacological activity. Using structure-based rational design, researchers developed and produced a humanized antibody inhibitor targeting human CTSB.

Key features of the study:

• This report provides an in-depth analysis of the global anti-cathepsin B market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti-cathepsin B market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Merck KGaA, Bio-Techne, BioVision Inc., Santa Cruz Biotechnology, Inc., MedChemExpress, BioCat GmbH, ApexBio Technology, Cayman Chemical, Selleck Chemicals, BOC Sciences, AG Scientific, Virobay Inc., and Abcam Plc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global anti-cathepsin B market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-cathepsin B market.

Detailed Segmentation:

• Global Anti-Cathepsin B Market, By Product Type :
  • Primary Antibodies
  • Proteins and Peptides
  • Lysates
• Global Anti-Cathepsin B Market, By Application :
  • Cancer
  • Traumatic Brain Injury
  • Ebola Infection
  • Fertility Treatment
  • Others
• Global Anti-Cathepsin B Market, By Technique :
  • Immunohistochemistry
  • Immunofluorescence
  • Western Blotting
  • ELISA
  • Flow Cytometry
  • Others
• Global Anti-Cathepsin B Market, By End User
  • Pharmaceutical Companies
  • Academic and Research Institutes
• Global Anti-Cathepsin B Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Merck KGaA
  • Bio-Techne
  • BioVision Inc.
  • Santa Cruz Biotechnology, Inc.
  • MedChemExpress
  • BioCat GmbH
  • ApexBio Technology
  • Cayman Chemical
  • Selleck Chemicals
  • BOC Sciences
  • AG Scientific
  • Virobay Inc.
  • Abcam Plc.